Titan Current Deferred Revenue from 2010 to 2025
| TTNP Stock | USD 3.87 0.39 11.21% |
Current Deferred Revenue | First Reported 2001-12-31 | Previous Quarter 12 K | Current Value 12 K | Quarterly Volatility 3.4 M |
Check Titan Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Titan Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 95.8 K, Interest Expense of 31.7 K or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 36.84, Dividend Yield of 0.0015 or PTB Ratio of 1.14. Titan financial statements analysis is a perfect complement when working with Titan Pharmaceuticals Valuation or Volatility modules.
Titan | Current Deferred Revenue |
Latest Titan Pharmaceuticals' Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Titan Pharmaceuticals over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Titan Pharmaceuticals' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Titan Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Titan Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 2,536,254 | |
| Geometric Mean | 414,856 | |
| Coefficient Of Variation | 189.50 | |
| Mean Deviation | 3,307,280 | |
| Median | 313,000 | |
| Standard Deviation | 4,806,305 | |
| Sample Variance | 23.1T | |
| Range | 14.4M | |
| R-Value | (0.62) | |
| Mean Square Error | 15.1T | |
| R-Squared | 0.39 | |
| Significance | 0.01 | |
| Slope | (630,198) | |
| Total Sum of Squares | 346.5T |
Titan Current Deferred Revenue History
About Titan Pharmaceuticals Financial Statements
Titan Pharmaceuticals shareholders use historical fundamental indicators, such as Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although Titan Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Titan Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Titan Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 10.8 K | 10.3 K |
Additional Tools for Titan Stock Analysis
When running Titan Pharmaceuticals' price analysis, check to measure Titan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Titan Pharmaceuticals is operating at the current time. Most of Titan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Titan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Titan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Titan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.